

UNITED STATE PARTMENT OF COMMERCE

Patent and Trademark Offic

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR		ATT	ATTORNEY DOCKET NO.	
09/465,41	29 12/21/	99 BOUCHER		R	5470-250	
020792	020792 ⊦		, ¬	EXAMINER		
MYERS BIGEL SIBLEY & SAJOVEC		•	WANG. 9	<u> </u>		
PO BOX 31				ART UNIT	PAPER NUMBER	
RALEIGH 1	NC 27627			1617		
				DATE MAILED:	03/23/01	

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trad marks

	,	Application No.	Applicant(s)				
		09/465,429	BOUCHER, RICHARD C.				
	Office Action Summary	Examiner	Art Unit				
. ,		Shengjun Wang	1617				
Th MAILING DATE of this communication appears on the cover shet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status							
1)	Responsive to communication(s) filed on						
2a)□	71110 4041011 10 1 11111 1—1	his action is non-final.					
3)	with the standard expense are a formal matters, prosecution as to the merits is						
Disposition of Claims							
4)⊠ Claim(s) <u>1-30</u> is/are pending in the application.							
4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
6) Claim(s) is/are rejected.							
7) Claim(s) is/are objected to.							
8) \boxtimes Claims <u>1-30</u> are subject to restriction and/or election requirement.							
Application Papers							
9) The specification is objected to by the Examiner.							
10) The drawing(s) filed on is/are objected to by the Examiner.							
11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved.							
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. \$ 119							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. \$ 119(a)-(d) or (f).							
a) ☐ All b) ☐ Some * c) ☐ None of:							
	1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No							
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
14) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).							
Attachmer	nt(s)						
15) No	tice of References Cited (PTO-892) tice of Draftsperson's Patent Drawing Review (PTO-948) ormation Disclosure Statement(s) (PTO-1449) Paper No(s	19) Notice of Informa	ary (PTO-413) Paper No(s) al Patent Application (PTO-152)				

Office Action Summary

Art Unit: 1617

DETAILED ACTION

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - Claims 1-21, drawn to a method for treatment of chronic obstructive pulmonary disease, classified in class 514, subclass 23, 724.
 - II. Claims 22-29, drawn to a method of administering an active agent to an airway surface, classified in class 514, subclass 23, 724.
 - III. Claim 30, drawn to a method for lavage of a lung of a patient in need, classified in class 514, subclass 23, 724.
- 1. Inventions Group I III are unrelated from each other. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions have different effects, hosts. They therefore have different issues regarding patentability and enablement and represent patentable distinct subject matter.
- 2. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Art Unit: 1617

Species Election

If Group I is elected, following species election is required.

3. This application contains claims directed to the following patentably distinct species of the claimed invention: a) osmolytes (claims 2-13); and b) the subjects (claims 15-19).

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1, 14 and 20-21 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

If group II is elected, following species election is required,

Art Unit: 1617

4. This application contains claims directed to the following patentably distinct species of the claimed invention: the active agents.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, 22 is generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the

Art Unit: 1617

application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shengjun Wang, Ph.D. whose telephone number is (703) 308-4554. The examiner can normally be reached on Monday-Friday from 8:30 to 5:00.

6. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Minna Moezie, J.D., can be reached on (703) 308-4612. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

Shengjun Wang

5.60つ

AU 1617

March 21, 2001

BUSSELL/TRAVERS
DRIMARY EXAMINER